All News

FDA clears perioperative Keytruda + Padcev for all patients with muscle-invasive bladder cancer, establishing a new cisplatin-independent standard of care.

Michigan has confirmed more than 1500 cyclospora cases as officials investigate the source of one of the nation's largest foodborne parasite outbreaks.

6 leading AI chatbots scored below 28% on a colorectal cancer knowledge test when barred from reasoning, raising fresh safety concerns for clinical use.

Phase 3 TRANSCEND shows setmelanotide cuts BMI and hunger in acquired hypothalamic obesity, signaling a new targeted option after hypothalamic injury.

Findings from CRISPR-edited stem cell–derived islets suggest SMOC1 functions as a physiological stabilizer of NKX6.1-positive β-cell identity.

Two studies identify molecular targets that could help preserve insulin-producing cell function.

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A study finds that 1- and 3-month dual antiplatelet therapy reduces bleeding vs standard regimens in patients at high bleeding risk.

Explore the biggest FDA PDUFA decisions expected in 2026, including gedatolisib, iberdomide, zidesamtinib, bepirovirsen, and anito-cel.

Benchmarking and interoperability reveal outlier utilization early, helping health leaders prevent fraud, waste, and abuse while strengthening compliance and value-based performance.

The expanded approval, based on the phase 3 WIL-33 trial, gives children with von Willebrand disease access to routine bleeding prophylaxis.

Ebola cases hit 1708 as unpaid health workers strike, further straining an outbreak response the World Health Organization says is outpacing containment.

Quest Diagnostics is integrating its Haystack MRD and genomic profiling tests into Flatiron's OncoEMR, starting with an AON community oncology pilot.

Vera's atacicept (Trutakna) wins FDA accelerated approval after a 46% proteinuria drop in the ORIGIN 3 trial.

A UK Biobank analysis found that IL-6, but not hsCRP, modified the association between elevated lipoprotein(a) and coronary artery disease risk.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care

A retrospective cohort study found stable blood pressure alongside significant reductions in LVOT gradients, regardless of hypertension status.

Secondary analysis of the STAR trial finds hypoglossal nerve stimulation cut hypoxic burden by 76.6%, even in some AHI-defined nonresponders.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

Slated to run through December 31, 2027, the Medicare GLP-1 Bridge was originally supposed to run for only 6 months.

The FDA advisory committee supports Moderna’s mRNA-1010 flu vaccine for adults 50-plus, with an August 5 PDUFA decision pending for mFlusiva.

A secret shopper study found 9 in 10 online GLP-1 sellers issued prescriptions, often with minimal screening for eating disorders or clinical risk.

A Brown University–led review synthesizes GDMT, comorbidity management, and emerging therapies into a hospital-based framework for HFpEF.

Adults treated with insulin showed sustained A1C improvements and fewer acute care visits among patients whose CGM was initiated in primary care compared with similar patients who did not initiate CGM.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.

A meta-analysis of 39 studies found similar or slightly better cancer survival for Black veterans compared with White veterans in the VHA.